カテゴリ： Kuick Research, 医療/バイオ

ナノ粒子ドラッグデリバリーの世界市場

◆英語タイトル：Global Nanoparticle Drug Delivery Market, Dosage, Price and Clinical Pipeline Outlook 2024
◆商品コード：DATA809010
◆発行会社（リサーチ会社）：KuicK Research
◆発行日：2018年4月
◆ページ数：480
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆調査対象地域：グローバル
◆販売価格オプション（消費税別）
Single UserUSD2,400 ⇒換算￥264,000見積依頼/購入/質問フォーム
Multi UserUSD4,800 ⇒換算￥528,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はKuicK Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
※KuicK Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

 【レポートの概要】

“Global Nanoparticle Drug Delivery Market, Dosage, Price & Clinical Pipeline Outlook 2024” Report Highlights:
• Nanoparticle Drug Market: US$ 200 Billion Opportunity By 2024
• Global Pipeline For Nanoparticle Drug: 231 Drugs
• Drugs In & Above Phase II Trials: 33 Drugs
• Marketed Nanoparticle Drugs: 13 Drugs
• Dosage, Price & Patent Analysis Of Key Drugs
• Upcoming Nanoparticle Drug Delivery Techniques
• Global Nanoparticle Drug Clinical Pipeline by Company, Indication & Phase

Drug delivery plays a significant role in determining the therapeutic outcome of a treatment. The limitations of conventional drug delivery system such as low bioavailability of therapeutics, poor patient compliance and fluctuation in concentration has led to a dire need for the development of new, better and safer delivery method with enhanced therapeutic outcome and safety.

The practice of drug delivery has changed dramatically in the past few decades with substantial changes being anticipated in the future. An emerging method that clearly stands out is the use of nanotechnology in drug delivery which utilizes specially designed nanoparticles to enhance drug delivery more effectively and precisely with additional advantages such as longer circulation delivery, longer half-lives, better bioavailability, improved pharmacokinetics and reduced side effects.

Additionally, nanoparticles also have the ability to transport drug molecules across the blood brain barrier which can be exploited to develop revolutionizing therapeutics for clinical conditions such as Parkinson’s disease, Alzheimer’s disease, schizophrenia and depression. It has also raised hope in complex disease like brain tumor – which is currently impossible to treat with conventional drug delivery methods.

An insight into the market trends shows that the ability of nanoparticles to enhance therapeutic outcome by a significant margin has led pharmaceutical companies to develop nanoparticle formulation of popular drugs like Megace ES(Enhanced Stability), Estrasorb (estradiol topical emulsion)and Triglide(Nanocrystal formulation of Tricor). Nanoparticle formulations of popular cancer therapeutics like Doxorubicin and Taxol has also been well received in the cancer therapeutic segment due to longer half-lives and reduced side effects.

Advancement in nanotechnology has resulted in the entry of many types of nanoparticles in the market. Nanocrystal and liposomes are currently the most popular nanoparticles in use, followed by micelles and dendrimers. Nanocrystal, liposomal and micelle formulations of therapeutics are being developed and marketed which is bound to increase the market size in the future.

Geographical Analysis of the Nanoparticle drug delivery method projects the increasing dominance of US with more than 40% of the global market, followed by Europe. However, the market size is anticipated to increase in the Asia Pacific and Latin American region during the forecast period due to multiple growth factors supporting the analysis, such as increase in patient base and the rising interest of key players like Johnson & Johnson and Novartis in the region.

KuicK Research Estimates the Global nanoparticle drug market to reach over US$ 200 Billion by 2024 at a CAGR of 10%. Growth promoting factors like increase in global prevalence of various clinical indications like cancer, diabetes and rheumatoid arthritis are bound to fuel the market growth with oncology being the dominant segment. The increasing demand for effective treatment methods to provide for the rising pool of patients are expected to help the segment retain dominance over the report’s forecast period as well.

The nanoparticles drug delivery market however faces some major challenges that are anticipated to hamper with its future growth. High demand of investments, scientific and technical limitations and overcrowding of vendors and marketing challenges such as exorbitant pricing of therapeutics, limited market penetration and low awareness are hurdles that need to be taken care of to enhance the potential of nanoparticle drug delivery segment.

KuicK Research report on global nanoparticle drug delivery market provides an in-depth analysis of the market with special emphasis on the Global market size, current market trends, dynamics and other factors that might have an impact on the market. Comparative price, dosage and therapy cost analysis of Original drugs with Nanoparticle formulations analyses the promising potential of Nanoparticle drug delivery, ultimately proving its superiority. KuicK Research analysis is based on extensive research from both primary and secondary sources, highlighting the market opportunities regionally and ensuring an optimistic future forecast of the global nanoparticles drug delivery market.

【レポートの目次】

1. Nanoparticles – Revolutionizing Drug Delivery Method
1.1 Prologue to Targeted Drug Delivery by Nanoparticles
1.2 Nanoparticle Drug Delivery –Enhancing the Efficacy of Therapeutics by Nanotechnology

2. Need for Nanoparticle Drug Delivery
2.1 Limitations of Traditional Drug Delivery Techniques
2.2 Rising Demand for Better Targeted Drug Delivery Techniques in the Oncology Segment

3. Superiority of Nanoparticle Based Drug Delivery over Traditional Drug Delivery
3.1 Better Therapeutic Outcome than Conventional Drug Delivery Methods
3.2 Role of Nanoparticles in Better Diagnosis of Cancer

4. Importance of Nanoparticle Drug Delivery in Cancer Therapy
4.1 Wide Application of Nanoparticles in Cancer Therapy
4.2 Mechanisms of Nanoparticle Internalization in Cancer Cells for Imaging & Therapy

5. Existing Techniques For Nanoparticle Drug Delivery
5.1 Nanocrystals
5.2 Liposomes
5.3 Dendrimers
5.4 Micelle Based Drug Delivery

6. Upcoming Nanoparticle Drug Delivery Techniques
6.1 Polymeric Nanoparticles
6.2 Metal based Nanoparticles (Gold, iron oxide)
6.3 Fullerenes & Carbon Nanotube
6.4 Quantum Dots Delivery

7. Global Nanoparticle Drug Market Overview
7.1 Current Market Scenario
7.2 Global Nanoparticle Drug Clinical Pipeline Overview

8. Price & Dosage Analysis of Commercially Available Nanoparticle Therapeutics
8.1 Liposomal Doxorubicin
8.1.1 Availability, Price & Mechanism of Action
8.1.2 Dosage in Various Clinical Indications
8.1.3 Liposomal Doxorubicin (Nanoparticle) v/s Traditional Doxorubicin – Comparative Analysis
8.2 Amphotericin
8.2.1 Availability, Price & Mechanism of Action
8.2.2 Dosage by Indication
8.2.3 Comparative Analysis- Conventional Amphotericin B v/s Nanoparticle Formulations
8.3 Paclitaxel (Taxol, Onxal)
8.3.1 Availability,Price & Mechanism of Action
8.3.2 Dosage Analysis in Various Types of Cancer
8.3.3 Paclitaxel v/s Abraxane(liposomal)
8.4 Sirolimus (Rapamune)
8.4.1 Availability,Price & Mechanism of Action
8.4.2 Rapamune – Dosage Analysis
8.5 Emend (Aprepitant Nanocrystal)
8.5.1 Availability & Price
8.5.2 Dosage Analysis
8.6 Megace ES (Enhanced Stability)
8.6.1 Availability, Price & Mechanism of Action
8.6.2 Comparative Dosage Analyis – Megace v/s Megace ES
8.7 Estradiol Topical Emulsion(Estrasorb)
8.8 Other Nanoparticle Therapeutic Formulations
8.8.1 Feraheme
8.8.2 Triglide – Nanocrystal Version of Tricor

9. Nanoparticle Drug Delivery – Market Trend & Patent Distribution Analysis
9.1 Patent Filing Status in Nanoparticle Drug Delivery
9.2 Patent Distribution by Nanomaterial Type
9.3 Patent Distribution by Stimulus
9.4 Patent Distribution by Route of Administration & Forms of Drug Delivery

10. Driving Factors of Nanoparticle Drug Delivery Market
10.1 Increasing Prevalence of Disease & the Need for Better Therapeutics
10.2 Better Reliability & Safety than Conventional Therapeutics
10.3 Advancement in Research & Development
10.4 Promising Investment & Market Potential
10.5 Rapid Advancement in Innovative and Superior Technology

11. Challenging Aspects of Nanoparticle Drug Delivery Segment
11.1 Highly Expensive Technique & Nanoparticle Products
11.2 Scientific & Technical Limitation Related to Nanoparticles Drug Delivery
11.3 Regional Limitation & Low Market Penetrance
11.4 Dominance of Conventional Drug Delivery Segment

12. Future Forecast & Market Analysis of Global Nanoparticle Drug Delivery Market

13. Global Nanoparticle Drug Clinical Pipeline by Company, Indication & Phase
13.1 Unknown
13.2 Research
13.3 Preclinical
13.4 Clinical
13.5 Phase-I
13.6 Phase-I/II
13.7 Phase-II
13.8 Phase-II/III
13.9 Phase-III
13.10 Preregistration
13.11 Registered

14. Marketed Nanoparticle Drug Clinical Insight by Company & Indication
14.1 Rilpivirine (Edurant)
14.2 Albumin-Bound Paclitaxel (Abraxane, Coraxane & Coroxane)
14.3 Meloxicam (VIVLODEX)
14.4 Ferumoxytol (Feraheme & Rienso)
14.5 Paclitaxel Liposomal – Sun Pharma Advanced Research Company
14.6 Fenofibrate (Lipanthyl & TriCor)
14.7 Doxorubicin Liposomal (Caelyx & Doxil)
14.8 Vincristine Liposomal (Marqibo)
14.9 Fenofibrate (Triglide)
14.10 Rexin-G
14.11 Estradiol Topical (Estrasorb)
14.12 Glycyrrhiza/Phosphatidylcholine (Phosphogliv)
14.13 Paclitaxel Nanoparticle (Nanoxel)

15. Competitive Landscape
15.1 Abraxis BioScience
15.2 Access Pharmaceuticals
15.3 Alnylam Pharmaceuticals
15.4 Amgen
15.5 Arrowhead Research
15.6 BIND Therapeutics
15.7 Cadila Healthcare
15.8 Celegen Corporation
15.9 Celsion Corporation
15.10 Genzyme Corporation
15.11 Merck
15.12 NanoCarrier
15.13 Nippon Kayaku
15.14 Nanobiotix
15.15 Novavax
15.16 Pfizer
15.17 Roche
15.18 Samyang
15.19 Sanofi
15.20 Takeda Pharmaceutical

Figure 1-1: Evolution of Nanoparticle Drug Delivery
Figure 1-2: Different Drug Delivery Routes
Figure 1-3: Organic Nanoparticles Used in Drug Delivery
Figure 2-1: Limitations of Traditional Drug Delivery Therapy
Figure 2-2: Global- Drug Delivery Segmentation by Route of Administration (%), 2017
Figure 3-1: Superior Characteristic of Nanoparticle Drug Delivery
Figure 3-2: Application of Nanoparticles in Diagnosis
Figure 4-1: Inorganic Nanoparticles Used in Drug Delivery
Figure 4-2: Nanoparticle - Application in Imaging Techniques (%), 2017
Figure 5-1: Nanoparticles Market Segmentation by Types
Figure 5-2: Global- Nanoparticle Drug Delivery Segmentation by Technology (%), 2017
Figure 5-3: Liposome Drug Delivery in Action
Figure 5-4: Dendrimer Nanoparticle in Drug Delivery
Figure 6-1: Gold Nanoparticles in Drug Delivery
Figure 6-2: Fullerenes Being Used as Vectors (Carrying Agents)
Figure 6-3: Quantum Dots in Cancer Therapy
Figure 7-1: Global Nanoparticle Drug Market (US$ Billion), 2013-2017
Figure 7-2: Global - Nanoparticle Drug Clinical Pipeline by Phase (%), 2018 till 2024
Figure 7-3: Global Nanoparticle Clinical Pipeline by Phase (%),2018 till 2024
Figure 8-1: Liposomal Doxorubicin - Availability by Concentration (ml)
Figure 8-2: Adriamycin - Price Analysis (US$/ml), 2018
Figure 8-3: Lipodox 50- Price Analysis (US$), 2018
Figure 8-4: Doxil- Dosage analysis for Ovarian Cancer (mg/m2)
Figure 8-5: Doxil - Dosage Analysis for Kaposi's sarcoma
Figure 8-6: Liposomal Doxorubicin - Dosage Analysis in Multiple Myeloma
Figure 8-7: Doxorubicin (Nanoparticle Variant)- Average Price Analysis (US$/ml), 2018
Figure 8-8: Comparative Dosage Analysis andndash; Traditional Doxorubicin v/s Liposomal Doxorubicin (mg/m2)
Figure 8-9: Doxorubicin- Comparative Price Analysis (US$/mg), 2018
Figure 8-10: Amphotericin B andndash; Availability by Concentration (mg/vial)
Figure 8-11: Conventional Amphotericin B- Dosage Analysis for Adult Fungal Infections (mg/kg)
Figure 8-12: Amphotericin B - Dosage Analysis in Pediatric Fungal Infection (mg/kg)
Figure 8-13: Liposomal Amphotericin B- Dosage Analysis by Indication (mg/kg)
Figure 8-14: Amphotericin B andndash; Comparative Daily Dosage Analysis by Formulation (mg/kg), 2018
Figure 8-15: Amphotericin B-Comparative Price Analysis by Formulation per Day (US$), 2018
Figure 8-16: Comparative Price Analysis andndash; Amphotericin B Nanoparticle Formulations (US$), 2018
Figure 8-17: Paclitaxel - Availability by Concentration (mg and ml)
Figure 8-18: Paclitaxel - Working Mechanism
Figure 8-19: Abraxane- Dosage Analysis by Cancer (mg/Cycle)
Figure 8-20: Paclitaxel Dosage Analysis by Cancer (mg/m2)
Figure 8-21: Price Analysis- Paclitaxel v/s Abraxane (US$), 2018
Figure 8-22: Paclitaxel v/s Abraxane andndash;Comparative Positive Response Rate (%)
Figure 8-23: Rapamune - Availability of Formulations (mg)
Figure 8-24: Rapamune - Cost Analysis by Formulation (US$), 2018
Figure 8-25: Rapamune - Dosage for Low Immune Risk Patients (mg)
Figure 8-26: Rapamune - Dosage for High Immunologic Risk (mg)
Figure 8-27: Emend - Price and Availability (US$), 2018
Figure 8-28: Emend - Dosage Analysis (mg/day)
Figure 8-29: Dosage Analysis - Megace v/s Megace ES (mg/day)
Figure 8-30: Megace v/s Megace ES - Comparative Price Analysis (US$), 2018
Figure 8-31: Estrasorb- Price Analysis (US$), 2018
Figure 8-32: Feraheme - Dosage Analysis (mg/ml)
Figure 8-33: Triglide - Availability by Concentration (mg)
Figure 8-34: Comparative Price Analysis -Triglide and Tricor (US$/Pack), 2018
Figure 9-1: Global- Patent Analysis by Cancer Types (Number), 2016
Figure 9-2: Global andndash; Nanoparticle Patent Filing Status by Region (Numbers), 2016
Figure 9-3: Global- Patent Distribution by Material Type (Numbers), 2016
Figure 9-4: Stimulus of Nanoparticles to Various Factors
Figure 9-5: Global- Patent Distribution by Stimulus (Numbers), 2016
Figure 10-1: Nanoparticle Drug Delivery - Driving Factors
Figure 10-2: Global - Nanoparticle Research in Cancer Segment (By number)
Figure 10-3: Magnetic Nanoparticle - Recent Advances in Drug Delivery
Figure 11-1: Nanoparticle Drug Delivery Market Challenges
Figure 12-1: Global - Nanoparticle Drug Deliver Dominance by Region (%), 2017
Figure 12-2: Global- Nanoparticle Drug Market (US$ Billion), 2018-2024
Figure 12-3: Global- Gold Nanoparticles Future Forecast (US$ Million), 2018 - 2024
Figure 12-4: Global - Investments in the Nanoparticle Drug Delivery Segment (US$ Billion), 2013-2017
Figure 15-1: Arrowhead Research Corporation Clinical Pipeline
Figure 15-2: NanoCarrier Clinical Pipeline

Table 5-1: List Of Commercially Available Nanocrystal Drugs and Their Indication
Table 5-2: Liposome Based Drugs - Current Status
Table 5-3: Current Market Status of Dendrimers
Table 6-4: Traditional Doxorubicin v/s Nanoparticle Doxorubicin

【免責事項】
https://www.marketreport.jp/reports-disclaimer
★医療情報レポート[ナノ粒子ドラッグデリバリーの世界市場]についてメールでお問い合わせはこちら

※関連の医療情報レポート

  1. 癌ナノ医療の世界市場見通し
    DATA611010 / Kuick Research / 2016年11月 / ...Over the past several years, many innovative and revolutionary techniques have been developed in order to treat cancer. These techniques range from basic surgical removal to X-ray irradiation to system wide flooding with anticancer agents. However, each of these approaches has its own series of undesirable side effects that are both dangerous and damaging to the overall health of the patient. On the contrary, recent breakthroughs in nanomedicine have managed to change all that. Now at last there is hope for a cure that is effective and can be made it safe. Use of nanomedicines for cancer is one of...
  2. 癌チューブリン阻害剤の世界市場・治験インサイト
    KUIK80305 / Kuick Research / 2018年2月 / ...“Global Cancer Tubulin Inhibitors Market & Clinical Trial Insight 2024” report gives comprehensive insight on the clinical and non-clinical parameters related to the emergence and development of role of tubulin inhibitors in the cancer therapy. Report highlights the clinical development of more than 70 cancer tubulin inhibitors in pipeline and shares in-depth dosage/price analysis of 10 cancer tubulin inhibitors commercially available in the market. “Global Cancer Tubulin Inhibitors Market & Clinical Trial Insight 2024” Report highlights: • Clinical Insight on 70 Tubulin Inhibitors in pipeline • Dosage & Price Analysis of 10 Commercialized Drugs • Patent Approval, Expiry Year &...
  3. 放出制御ドラッグデリバリーの世界市場
    KUIK706002 / KuicK Research / 2017年5月 / ...“Global Controlled Drug Delivery Market & Clinical Trial Outlook 2022” report gives comprehensive clinical and non-clinical insight on the emergence and integration of controlled release technology in the drug delivery. Report highlights the ongoing development of more than 300 controlled release drugs in clinical trials and helps to analyze the existing clinical mechanism of 133 commercially available controlled release drugs in the market. The fundamentals and application of controlled release drug delivery encapsulated in the report helps to identify the various aspect of the growing controlled release drug delivery market. “Global Controlled Drug Delivery Market & Clinical Trial Outlook 2022”...
  4. PARP阻害剤がん治療の世界市場
    DATA809009 / KuicK Research / 2018年4月 / ...“Global PARP Inhibitors Cancer Therapy Market, Price, Dosage & Clinical Pipeline Outlook 2023” report highlights: • Current Market Trends & Development Scenario • Drug Availability, Dosage & Treatment Schedule • Commercially Available Drugs Price Analysis • Global Cancer PARP Inhibitors Clinical Pipeline Overview: 31 Drugs • Clinical & Patent Insight on Commercially Available Drugs: 3 Drugs • Market Segmentation by Drug Patent & Dales Conventional therapies like surgery, radiotherapy and chemotherapies are currently the dominant form of cancer treatment globally. However, majority of these methods have several limitations with multiple adverse effects which has led to the emergence of much...
  5. 癌治療用ナノメディシンの世界市場及びパイプラインインサイト
    KUCK502264 / KuicK Research / 2015年2月 / ...During the last decade, there has been significant impact of the emergence of nanotechnology on clinical therapeutics. The pharmaceutical industry has witnessed advances in biocompatible nanoscale drug carriers in the form of liposomes and polymeric nanparticles which have the potential to deliver numerous drugs with more efficiency and safety. The advantages of nanoparticle drug delivery, specifically, at the systemic level, include longer circulation half-lives, improved pharmacokinetics and reduced side effects which are major reasons for its increasing popularity. In the field of cancer therapy, the nanoparticles could possibly depend heavily on the enhanced permeability and retention effect which is caused...
  6. 癌細胞増殖阻害剤の世界市場：チロシンキナーゼ阻害薬、HDAC阻害薬、MTORタンパク質阻害薬、PI3K阻害薬、プロテアソーム阻害薬
    KUIK505181 / Kuick Research / 2015年5月 / 当調査レポートでは、インスリンパッチの世界市場について調査・分析し、以下の構成でお届けいたします。 ・インスリンパッチの概要 ・インスリンパッチ治療の仕組み ・インスリンパッチの世界市場概要 ・インスリンパッチの世界市場動態 ・インスリンパッチの世界市場展望 ・インスリンパッチの開発パイプライン（治験）動向 ・停止・中止されたインスリンパッチ ・主要企業分析...Transdermal drug delivery is one of the oldest methods that have been used by physicians to alleviate patients’ medical condition. Patches are recent inventions of pharmaceutical companies for those patient populations who can’t be administered with conventional drugs. They are applied over the skin from which drug is released in controlled manner followed by entry into the body. Topical drugs are also applied on skin but their effect is local and they do not become systemic. Over the years, several modalities for transfer of insulin have been developed by investigators. They have several benefits but they are not as beneficial...
  7. ナノ化学療法の世界市場
    KUIK706005 / Kuick Research / 2017年5月 / ...“Global Nano Chemotherapy Market & Clinical Trials Outlook 2022” report highlights the current development in the in the field of nano chemotherapy. Report gives comprehensive insight on various clinical and non-clinical parameters associated with the expansion of global nano chemotherapeutics market. The clinical and pricing insight on chemotherapeutics nanoformulations of approved drugs helps to understand the current market scenario of the nano chemotherapeutics. Nano chemotherapy is emerging as an important anti-cancer modality by supplementing the traditional chemotherapy. The main aim of nano chemotherapeutics is to improve the therapeutic efficacy of currently available chemotherapeutic agents by combining it with a nano...
  8. 制御放出式薬物デリバリー市場及びパイプライン分析
    Kuick-40529 / Kuick Research / 2014年5月 / ...Controlled drug delivery refers to a system combining the formulation components and devices with the objective of releasing a drug at a predictable rate. The controlled drug delivery system makes it possible in vivo, irrespective of whether the administration of the drug is done through the injected or non-injected route. A controlled drug delivery is observed to occur when a natural or a synthetic polymer is carefully combined with a drug in a manner which enables the release of the active agent from the material in the pre-specified method. As compared to other forms of targeted drug delivery, the controlled...
  9. 世界の鼻腔内薬物送達市場及び開発パイプライン
    KUIK409142 / Kuick Research / 2014年9月 / ...Intranasal drug delivery has evolved in the recent years as a significant method of delivering drugs through the nasal route. This method has been identified to have all the potential to achieve significant milestones in the pharmaceutical industry, as it is largely driven by its capability to cure local infections and chronic allergies. The human nose, which has a unique vascular structure, makes it specifically accessible for delivering small molecule drugs and biologics. By taking advantage of the conducive healthcare trends and changing demography, the intranasal drug delivery route is likely to capture the popularity of other leading methods of...
  10. CAR-T細胞療法の世界市場
    KUIK706006 / Kuick Research / 2017年4月 / ...“Global CAR T Cell Therapy Market & Clinical Trials Insight 2022” report highlights the ongoing clinical and non-clinical advancement in the field of Car T Cell Therapy. As per report findings, the promise of CAR modified T cell therapy derives from its combined immunologic benefits and include the specificity of a targeted antibody, the ability to expand the T cell population and the potential for long term persistence to facilitate the ongoing tumor surveillance. The success in early phase trials, assess the feasibility of evaluating the treatment modality across the multiple centers and in larger patients. Currently, there are 99...

◆H&Iグローバルリサーチ株式会社のお客様（例）◆